Yifan Pharmaceutical Hits Day High with Strong 3.8% Intraday Surge

Yifan Pharmaceutical Co., Ltd. has experienced a notable increase of 3.8% on March 10, 2026, reaching an intraday high of CNY 13.46. This performance stands out against the backdrop of the China Shanghai Composite, which only gained 0.65% on the same day. Over the past week, Yifan has shown a modest increase of 0.6%, while its one-month performance reflects a more substantial rise of 9.21%. Despite these short-term gains, Yifan's long-term growth metrics indicate challenges, with net sales declining at an annual rate of -1.21% and operating profit decreasing by -21.20% over the last five years. The company's return on capital employed (ROCE) is relatively low at 2.72%, and it carries a debt-to-equity ratio that raises concerns about its financial leverage. On a positive note, Yifan has reported positive results for the last five consecutive quarters, with operating cash flow peaking at CNY 616.42 million. The stock's performance over the past year has yielded a return of 16.52%, alongside a significant profit increase of 152.2%.